Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1998-08-13
2000-10-10
Prats, Francisco
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
514824, 514 52, 514249, 514345, A61K 3578
Patent
active
061299189
ABSTRACT:
A method and composition are described for reducing the elevated plasma homocysteine level in mammals (humans) by oral administration of a therapeutically effective amount of Allium plants or extracts thereof, preferably garlic, with or without one or more vitamins such as B.sub.6, B.sub.12 and folic acid in an acceptable pharmaceutical carrier. Enhanced effectiveness is achieved with a combination of Allium plants or extracts thereof, preferably garlic, with vitamins such as B.sub.6, B.sub.12 and folic acid. The described method and composition are effective for prevention, treating or ameliorating cardiovascular diseases such as myocardial infarction, stroke and multiple arteriosclerosis by the reduction or prevention of high levels of plasma homocysteine, one of the major causes for such diseases. Methods and compositions are disclosed.
REFERENCES:
patent: 4737364 (1988-04-01), Kalogris
patent: 5231114 (1993-07-01), Awazu
patent: 5612077 (1997-03-01), Hibi
Agarwal, Med. Res. Reviews 16(1):111-124, 1996.
Boushey, C.J., A Quantitative Assessm't of Plasma Homocysteine as a Risk Factor for Vasc. Disease, JAMA, 1995, 274: 1049-1057.
Perry, I.J., Prosp. study of serum tot. homocysteine conc. and risk of stroke in mid-age British men, The Lancet, 1995, 346: 1395-98.
Malinow, M.R., Homocyst(e)ine and arterial occlusive diseases, Journal of Int. Med., 1994; 236: 603-617.
Verhoef, P., Homocysteine Metabolism and risk of M.I.: Rel. with Vit.'s B6, B12, and Folate, Am. J. of Epidemiology, 1996, 143: 845-859.
McCulley, K.S., Homocysteine, Folate, Vitamin B6, and Cardio. Disease, JAMA, 1998, 279: 392-3.
Arnesen, E., Serum Total Homocysteine and Coronary Heart Disease, INt. Journal of Epidemiology, 1995, 24: 704-9.
Rosenberg, I.H., Homocysteine, Vitamins and Arterial Occ. Disease: An Overview, Am. Inst. of Nutrition. J. Nutr., 1996, 126: 1235S-1237S.
Bratterstrom, L., et al., Homocysteine and cysteine: det.'s of plasma levels in mid-aged and elderly sub.'s, J or Int. Med., 1994 236: 633-641.
Graham, I.M., et al., Plasma Homocysteine as Risk Factor for Vasc. Disease, JAMA, 1997, 277: 1775-1781.
Clarke, R., et al., Hyperhomocysteinemia: An Ind. risk factor for Vasc. Disease, The N.E. J. of Med., 1991, 324: 1149-1155.
Selhub, J., et al., Assoc. between Plasma Homocysteine Conc.'s and Extracranial carotid-artery stenosis, The N.E. J. of Med., 1995 332: 286-91.
Stampfer, M.J. et al., A Prospective Study of Plasma Homocyst(e)ine and Risk of M.I. in US Physicians, JAMA, 1992, 268: 877-881.
Cowley, G., The Heart Attackers, Newsweek, Aug. 11, 1997, 55-60.
Prats Francisco
Wakunaga of America Co., Ltd.
LandOfFree
Method and pharmaceutical composition for reducing serum homocys does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and pharmaceutical composition for reducing serum homocys, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and pharmaceutical composition for reducing serum homocys will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2254288